ACR-2316

N/A

Report date: 2024/11/02 20:00:07

NME

Base Information

Drug NameACR-2316

Drug Alias NameACR-2316

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSerine/threonine-protein kinase WEE1 inhibitorsMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase inhibitors

TargetsSerine/threonine-protein kinase WEE1Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAcrivon Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAcrivon Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A